Pulse Biosciences Inc Cash Flow Conversion Efficiency
Pulse Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Pulse Biosciences Inc (PLSE) has a cash flow conversion efficiency ratio of -0.188x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.71 Million) by net assets ($99.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pulse Biosciences Inc (2014–2025)
Cash flow conversion efficiency of Pulse Biosciences Inc from 2014 to 2025. This chart illustrates how Pulse Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PLSE share price today for real-time trading data and today's change.
Pulse Biosciences Inc Cash Flow Conversion Ratio Explained
Pulse Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pulse Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pulse Biosciences Inc ranked by their cash flow conversion efficiency. Also see PLSE market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WesBanco, Inc.
NASDAQ:WSBC
|
0.019x |
|
Atour Lifestyle Holdings Limited American Depositary Shares
NASDAQ:ATAT
|
0.247x |
|
Granite Real Estate Investment Trust
TO:GRT-UN
|
0.017x |
|
Turk Telekomunikasyon AS
IS:TTKOM
|
0.158x |
|
Unifirst Corporation
NYSE:UNF
|
0.023x |
|
USA Compression Partners LP
NYSE:USAC
|
0.507x |
|
Arcadis N.V.
AS:ARCAD
|
-0.096x |
|
Loomis AB ser. B
ST:LOOMIS
|
0.083x |
Annual Cash Flow Conversion Efficiency for Pulse Biosciences Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Pulse Biosciences Inc from 2014 to 2025. Review PLSE FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $80.66 Million | $-54.12 Million | -0.671x | -112.08% |
| 2024-12-31 | $114.86 Million | $-36.34 Million | -0.316x | +57.52% |
| 2023-12-31 | $44.36 Million | $-33.04 Million | -0.745x | -103.56% |
| 2022-12-31 | $-2.25 Million | $-47.01 Million | 20.913x | +1479.73% |
| 2021-12-31 | $35.69 Million | $-54.10 Million | -1.516x | +1.88% |
| 2020-12-31 | $22.89 Million | $-35.37 Million | -1.545x | -38.89% |
| 2019-12-31 | $30.74 Million | $-34.19 Million | -1.112x | -208.73% |
| 2018-12-31 | $66.33 Million | $-23.90 Million | -0.360x | -49.45% |
| 2017-12-31 | $45.99 Million | $-11.09 Million | -0.241x | +24.26% |
| 2016-12-31 | $25.30 Million | $-8.05 Million | -0.318x | -31.12% |
| 2015-12-31 | $13.67 Million | $-3.32 Million | -0.243x | -2153.35% |
| 2014-12-31 | $16.07 Million | $-173.14K | -0.011x | -- |
About Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac… Read more